[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![JamesEKrause Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1091405261741404162.png) Biotech Jim [@JamesEKrause](/creator/twitter/JamesEKrause) on x 12.6K followers
Created: 2025-07-22 20:46:12 UTC

Axsome Therapeutics had their "Frontiers in Brain Health R&D Day" ystdy, and I am parking the slide show. I am largely lured to $AXSM due to their expanding CNS pipeline, and the potential of AXS-05 in Alzheimer's Disease Agitation, amongst other reasons.  I point out slides 17-41 on ADA, for a thorough review of the ADVANCE and ACCORD series of Ph3 trials. 
 
The black-boxed #Rexulti (brexpiprazole) from Otsuka and Lundbeck is the only FDA-approved to treat agitation associated with dementia due to Alzheimer's disease.  

We shall see how the new FDA treats Axsome with this filing, but my view is that this drug far beats #Rexulti both in efficacy and in safety.  



![](https://pbs.twimg.com/media/GwfStFlXEAA2CgK.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947760109725356504/c:line.svg)

**Related Topics**
[$axsm](/topic/$axsm)

[Post Link](https://x.com/JamesEKrause/status/1947760109725356504)